IS5889A - Aðferð til að koma í veg fyrir eða tefja enduræðun sem á upptök í hollegg - Google Patents

Aðferð til að koma í veg fyrir eða tefja enduræðun sem á upptök í hollegg

Info

Publication number
IS5889A
IS5889A IS5889A IS5889A IS5889A IS 5889 A IS5889 A IS 5889A IS 5889 A IS5889 A IS 5889A IS 5889 A IS5889 A IS 5889A IS 5889 A IS5889 A IS 5889A
Authority
IS
Iceland
Prior art keywords
originates
catheter
preventing
delaying recurrence
recurrence
Prior art date
Application number
IS5889A
Other languages
English (en)
Inventor
Michael Black Donald
Original Assignee
Warner-Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company, , Delaware Corporation filed Critical Warner-Lambert Company, , Delaware Corporation
Publication of IS5889A publication Critical patent/IS5889A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
IS5889A 1998-09-30 2001-03-14 Aðferð til að koma í veg fyrir eða tefja enduræðun sem á upptök í hollegg IS5889A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30
PCT/US1999/015385 WO2000018395A1 (en) 1998-09-30 1999-07-08 Method for preventing or delaying catheter-based revascularization

Publications (1)

Publication Number Publication Date
IS5889A true IS5889A (is) 2001-03-14

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5889A IS5889A (is) 1998-09-30 2001-03-14 Aðferð til að koma í veg fyrir eða tefja enduræðun sem á upptök í hollegg

Country Status (34)

Country Link
US (1) US20080119561A1 (is)
EP (1) EP1117392B1 (is)
JP (1) JP2002525321A (is)
KR (1) KR20010079955A (is)
CN (1) CN1197565C (is)
AP (1) AP1708A (is)
AT (1) ATE260100T1 (is)
AU (1) AU768474B2 (is)
BG (1) BG105471A (is)
BR (1) BR9914098A (is)
CA (1) CA2343299C (is)
CZ (1) CZ20011035A3 (is)
DE (1) DE69915084T2 (is)
DK (1) DK1117392T3 (is)
EA (1) EA007427B1 (is)
EE (1) EE200100199A (is)
ES (1) ES2214872T3 (is)
HR (1) HRP20010236A2 (is)
HU (1) HUP0103648A3 (is)
ID (1) ID30255A (is)
IL (2) IL141953A0 (is)
IS (1) IS5889A (is)
NO (1) NO20011615L (is)
NZ (1) NZ510500A (is)
OA (1) OA11787A (is)
PL (1) PL346980A1 (is)
PT (1) PT1117392E (is)
SI (1) SI1117392T1 (is)
SK (1) SK4122001A3 (is)
TR (1) TR200100901T2 (is)
UA (1) UA73292C2 (is)
WO (1) WO2000018395A1 (is)
YU (1) YU23901A (is)
ZA (1) ZA200102230B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203326A3 (en) 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
AU2001264731A1 (en) * 2000-07-14 2002-01-30 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5807388A (en) * 1994-05-25 1998-09-15 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
AU3667297A (en) * 1996-07-09 1998-02-02 Merck & Co., Inc. Therapy for combined hyperlipidemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
UA73292C2 (en) 2005-07-15
CZ20011035A3 (cs) 2001-10-17
ES2214872T3 (es) 2004-09-16
CA2343299A1 (en) 2000-04-06
AU4975099A (en) 2000-04-17
ID30255A (id) 2001-11-15
BG105471A (bg) 2001-12-31
CN1342072A (zh) 2002-03-27
AP2001002112A0 (en) 2001-06-30
NO20011615L (no) 2001-04-24
EP1117392B1 (en) 2004-02-25
PL346980A1 (en) 2002-03-11
SK4122001A3 (en) 2002-06-04
BR9914098A (pt) 2001-07-31
OA11787A (en) 2005-07-26
YU23901A (sh) 2003-07-07
SI1117392T1 (en) 2004-06-30
EP1117392A1 (en) 2001-07-25
CA2343299C (en) 2008-04-01
AP1708A (en) 2007-01-10
EE200100199A (et) 2002-06-17
AU768474B2 (en) 2003-12-11
DE69915084T2 (de) 2004-07-22
DK1117392T3 (da) 2004-06-14
DE69915084D1 (de) 2004-04-01
HUP0103648A2 (hu) 2003-08-28
PT1117392E (pt) 2004-07-30
IL141953A (en) 2006-07-05
HUP0103648A3 (en) 2003-10-28
ATE260100T1 (de) 2004-03-15
JP2002525321A (ja) 2002-08-13
IL141953A0 (en) 2002-03-10
WO2000018395A1 (en) 2000-04-06
NO20011615D0 (no) 2001-03-29
TR200100901T2 (tr) 2001-08-21
CN1197565C (zh) 2005-04-20
KR20010079955A (ko) 2001-08-22
US20080119561A1 (en) 2008-05-22
EA200100370A1 (ru) 2001-10-22
NZ510500A (en) 2003-10-31
ZA200102230B (en) 2002-06-18
EA007427B1 (ru) 2006-10-27
HRP20010236A2 (en) 2002-04-30
HK1042436A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
IS2321B (is) Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum
GB2339407B (en) Methods for forming integrated circuits within substrates,and embedded circuits
NO20012940L (no) Fremgangsmåter og sammensetninger for å redusere permeabilitetene til underjordiske soner
DE69930806D1 (de) Verbesserungen der Zeitsynchronisierung in verteilten Systemen
PL366205A1 (en) Methods and systems for finding value and reducing risk
IL143674A0 (en) Metalloproteinase inhibitors, and the methods for making these
GB0118794D0 (en) Wafer edge engineering method and device
IS5885A (is) Lyfjagjafarkerfi til munninntöku sem veitir tíma-og rúmháða stjórnun á lyfjagjöf
EP1062432A4 (en) FIXING AND RELEASE SYSTEMS
AU2002222216A1 (en) Diffuse reflector and method
DE60033961D1 (de) Verzweigungs- und zurückbefehl
NO985099D0 (no) Flere-laterale br°nnborings-systemer og -fremgangsmÕter for Õ danne de samme
DK0928362T3 (da) Blokerende sammensætning til anvendelse i en underjordisk formation
ZA982517B (en) Novel inhibitors of the formation of soluble CD23 in humans.
IL144349A0 (en) Non-nucleoside reverse transcriptase inhibitors
IT1312195B1 (it) Proiettile stabilizzato in rotazione e procedimento per la suafabbricazione
SG83165A1 (en) Assembly fixture and method for variable vane assembly
IS5412A (is) Ísókínólín sem úrókínasa latar
DK0952337T3 (da) System til at orientere vindturbiner op mod vinden
GB2354219B (en) Method and system for exploiting natural resources under the seabed
ID30255A (id) Metoda untuk mencegah atau menunda revaskularisasi berdasarkan kateter
NO20030853D0 (no) Fremgangsmåte for kondisjonering av stående og flytende vannsystemer
GB2352523B (en) Fluid-gauging systems and methods
NO995420D0 (no) Gass- og faststoffreduserende slurry-fallrör
NO990939L (no) Anker av platetype, og fremgangsmÕte for Õ anbringe dette